Skip to main content
Premium Trial:

Request an Annual Quote

Desktop Genetics Licenses Genome Editing Assessment Tech

NEW YORK (GenomeWeb) – Desktop Genetics announced today that it has acquired an exclusive license to technology for the assessment of genome-editing efficacy from the Netherlands Cancer Institute (NKI).

Under the terms of the deal, London-based Desktop will have the exclusive global rights to TIDE — short for tracking of indels by decomposition — a web-based tool that quantifies the efficacy of genome-editing methods and identifies the predominant types of insertions and deletions in a targeted pool of cells. According to a paper published by the technology's developers at NKI, TIDE requires only two parallel PCR reactions followed by a pair of standard capillary sequencing analyses. The two resulting sequencing traces are then analyzed using special software.

Desktop said that TIDE will be added to its Deskgen Cloud CRISPR design platform. Additional terms of the deal were not disclosed.

"The free tools we offer allow scientists to efficiently store and manage their experiments, which could save them hours," Desktop Genetics CEO Riley Doyle said in a statement. "We look to continue providing a one-stop platform for accurate and reproducible CRISPR investigation design for academic and private institutions alike."